← Back to Home

FDA Approves At-Home Starting Dose of Leqembi, Removing One Infusion Barrier for Alzheimer’s Anti-Amyloid Treatment

A weekly subcutaneous autoinjector allows patients with early Alzheimer’s disease to begin lecanemab treatment at home, but it changes the route of administration, not the diagnosis, monitoring, or safety risks themselves.

By SURL BioNews

For treatment of early Alzheimer’s disease, whether a drug can fit into daily life often affects accessibility as much as efficacy. The U.S. FDA’s approval of Eisai and Biogen’s Leqembi IQLIK as an at-home starting dose of lecanemab means some patients do not have to begin with intravenous infusion at a medical facility, and can instead start anti-amyloid treatment with a once-weekly subcutaneous injection.

The FDA said the approval applies to patients with early Alzheimer’s disease, including those in the mild cognitive impairment or mild dementia stages, who meet the conditions for lecanemab treatment. Leqembi IQLIK is a subcutaneous formulation of lecanemab-irmb. The approved starting regimen is 500 mg weekly, administered with two 250 mg autoinjectors; Eisai and Biogen said each injection takes about 15 seconds.

The key to the decision is that regulators accepted existing intravenous clinical results as the foundation, supplemented by evidence on drug exposure and clearance of amyloid plaques in the brain for the subcutaneous formulation. Company data indicate that supporting evidence came from a subcutaneous substudy in the Phase 3 Clarity AD long-term extension study, showing that subcutaneous administration can achieve exposure comparable to intravenous administration and is expected to produce a similar amyloid plaque removal effect.

BioArctic also confirmed approval of the supplemental biologics license application and said that in the United States patients may use intravenous infusion or Leqembi IQLIK subcutaneous injection during treatment, switching between the two routes of administration when necessary. Eisai and Biogen plan for the product to be available in the United States through specialty pharmacies by the end of August 2026; this launch timing is a company plan, and actual use will still depend on physician judgment, reimbursement arrangements, and whether patients meet monitoring requirements.

**Background Context**

Leqembi is an antibody therapy targeting beta-amyloid protein aggregates in the brain. For this type of treatment, the barriers have not only been the drug itself, but also the diagnostic process, imaging or biomarker confirmation, infusion resources, and monitoring during treatment for ARIA and other risks related to brain swelling or bleeding. Subcutaneous injection partially moves the “in-clinic infusion” step out of medical facilities, but it does not remove the need for medical screening and safety follow-up.

Reuters reported that after the news was released, Biogen’s share price rose intraday. Some analysts believe the subcutaneous starting dose could improve convenience of access and differentiate Leqembi from competing drugs that still primarily rely on intravenous infusion. However, market accessibility will not necessarily translate automatically into broad use: early diagnosis rates, specialist capacity, insurance reimbursement, MRI monitoring, and patients’ acceptance of risk will still determine how far this at-home starting regimen can go.

Therefore, this approval is more like an institutional adjustment in which Alzheimer’s antibody therapy moves from a hospital-based procedure toward long-term chronic disease management. It makes administration closer to daily life, but also pushes a more practical question to the forefront: when treatment becomes easier to start, is the healthcare system also prepared to take on more precise screening, education, and follow-up?

References

  1. FDA
  2. Eisai US
  3. BioArctic via PR Newswire
  4. Reuters via Sahm Capital